The team also used a small-molecule inhibitor of the FABP family (BMS309403, which is thought to primarily target FABP4) and found that this not only significantly reduced tumor burden in a syngeneic, orthotopic mouse model, but also increased the sensitivity of cancer cells toward carboplatin both in vitro and in vivo, demonstrating the safety and efficacy of targeting FABP4 pharmacologically for ovarian cancer [37]. Here, FABP4 is linked to ovarian cancer.